This feature explores spin-offs or de-mergers, looking at the rationale for them and how they have performed, and asks if they can be a promising hunting ground for investors.One of the UK?s largest recent spin-offs was GSK?s (GSK) demerger of its consumer healthcare division in 2022.GSK reportedly rebuffed a £50 billion offer from personal goods giant Unilever (ULVR) to buy the division, named H

London?s FTSE 100 ended Tuesday morning how it started it, barely budging in cautious trade ahead of Wednesday?s US inflation report.Miners were on the up, as were oil majors, though that still could not lift the FTSE 100 into the green. Heavyweights such as drugmaker GSK, down 0.5% and defence firm BAE Systems, sliding 4.2%, were among those holding back London?s blue-chip benchmark.The FTSE 100

In a world of thousands of stocks, certain people just want to focus on ones that are doing well. If these stocks are part of a group with a snappy acronym or label, they must surely matter, right? That is the widespread view among the investment community.Investors love a narrative and what better way to hook people in than with a label that says, ?look at me?. The Magnificent Seven is the latest

Broad-based growth delivered in 2023Slow first quarter expected£500 million buyback launchedShares in Haleon (HLN) were marked 6% higher to 332.1p on Thursday after the consumer health colossus reported a robust finish to 2023, with fourth quarter organic sales growth of 7%, and said it will allocate £500 million to share buybacks in 2024.Despite competitive market conditions, the FTSE 100 firm

Oral pill meets late-stage trial goalsOver 82 million people infected each yearShares outperform year-to-datePharmaceutical giant GSK (GSK) said a late-stage trial of its oral antibiotic drug to treat gonorrhoea in adults and adolescents met it primary goals.Gonorrhoea is a sexually-transmitted infection affecting more than 82 million people globally a year and increases the risk of HIV infection.

BT CEO snaps up 400,000 sharesGSK CEO offloads £2.3 million sharesPoolbeg Pharma chairman ups his stakeAllison Kirkby CEO of BT (BT.A) has bought 400,000 shares at 107p for a total value of £428,000 on 20 February.The move comes as the telecoms giant announced that it was offloading its iconic ?BT Tower? in London?s Fitzrovia to MCR for £275 million.The company announced Kirkby?s appointment la

The end of the tax year is fast approaching and with it the opportunity to maximise your £20,000 ISA allowance for the year.In this article we have identified six names from a list of some of the most consistent funds and fund managers in the UK which could be a good fit for your tax wrapper. While we have aimed for a balance across different investment styles and asset classes this is not intend

While still easing, US consumer price inflation data came in hotter than expected on Tuesday, sending stock prices in London into the red on Tuesday.The FTSE 100 index closed down 61.41 points, 0.8%, at 7,512.28. The FTSE 250 ended down 280.10 points, 1.5%, at 18,923.83, and the AIM All-Share closed down 2.85 points, 0.4%, at 747.33.The Cboe UK 100 ended down 0.9% at 750.56, the Cboe UK 250 closed

European equities declined heading into Tuesday afternoon, as investors anxiously await a key US inflation report later.Meanwhile, robust UK unemployment data encouraged some to rethink when the Bank of England might start cutting interest rates, supporting the pound higher.The FTSE 100 index traded 20.66 points lower, 0.3%, at 7,553.03. The FTSE 250 was down 117.64 points, 0.6%, at 19,086.29, tho

Stock prices in London were mixed at the start of Monday afternoon, with the FTSE 100 down, as shares in some of its larger constituents struggled at the start of the week.The FTSE 100 index fell 11.34 points, 0.2%, at 7,561.24. The FTSE 250 is up 74.94 points, 0.4%, at 19,137.26, and the AIM All-Share added 1.39 points, 0.2%, at 748.80.The Cboe UK 100 fell 0.1% to 755.81, the Cboe UK 250 climbed

Stocks in London faded into the close losing momentum ahead of the first interest rate decision by the US central bank this year.The FTSE 100 index closed down 35.74 points, 0.5%, at 7,630.57. The FTSE 250 ended up 8.45 points, marginally up, at 19,357.95 and the AIM All-Share closed down 0.14 of a point, marginally lower, at 754.75.The Cboe UK 100 ended down 0.3% at 763.97, the Cboe UK 250 closed

London?s FTSE 100 went into the afternoon flat, with trade lacking conviction ahead of Wednesday?s main event, the Federal Reserve decision.US monetary policymakers are expected to wrap-up their two-day meeting with a hold to interest rates later.Before the decision is announced, there is a US jobs report from ADP at 1315 GMT, a precursor to Friday?s nonfarms. Elsewhere, the economic calendar has

Q4 sales and profit beat expectationsRaised long-term guidanceNovo Nordisk shares hit new highGlobal biopharma company GSK (GSK) delivered better-than-expected fourth-quarter sales and profit growth and raised its long-term guidance.A strong finish means full-year performance came in at the upper end of upgraded guidance given at the end of the third quarter.The market shrugged off the ?beat and r

Stock prices in London had little direction on Wednesday morning, ahead of crucial interest rate decisions by the US Federal Reserve and the Bank of England.The FTSE 100 index opened up 2.76 points at 7,669.07. The FTSE 250 was down 11.48 points at 19,338.02, and the AIM All-Share was down 0.19 of a points at 754.70.The Cboe UK 100 was down 0.1% at 765.96, the Cboe UK 250 was down 0.1% at 16,798.2

Stocks in London climbed on hopes earnings from two of the biggest names in US business would spark further upward momentum in equities.The FTSE 100 index closed up 33.57 points, 0.4%, at 7,666.31. The FTSE 250 ended up 38.34 points, 0.2%, at 19,349.50, and the AIM All-Share closed up 4.61 points, 0.6%, at 754.89.The Cboe UK 100 ended up 0.5% at 766.38, the Cboe UK 250 closed up 0.3% at 16,807.59,

Compared to other retail verticals, Christmas is relatively less important to the pet care market. Nevertheless, UK market leader Pets at Home (PETS) will need to reassure investors that retail like-for-like sales momentum has been sustained when it bounds in with a third-quarter trading update on 30 January.Liberum Capital doesn't expect any reporting surprises, although the broker does remain ?c

Shares in global bio-pharmaceutical firm GSK (GSK) have performed poorly in recent times, relatively speaking, lagging the FTSE 100 index by 4% and peer AstraZeneca (AZN) by a whopping 87% over the last five years.Operationally there have been clear signs of improvement, with the company delivering strong trading updates throughout 2023 which saw the shares finally outperform both the blue-chip in

A respected analyst is warning the ?relentless? pace of de-equitisation driven by depressed UK stock market valuations will continue unless action is taken.Low valuations are making the UK stock market an attractive hunting ground for acquirers and are a key factor behind the ?minimal? IPO (initial public offering) activity of the last two years which needs to be ?actively addressed? Peel Hunt?s (

Stock prices in London closed lower on Wednesday, as investors await the latest meeting minutes from the US Federal Reserve.The FTSE 100 index closed down 39.19 points, 0.5%, at 7,682.33. The FTSE 250 ended down 185.40 points, 1.0%, at 19,326.40, and the AIM All-Share closed down 7.40 points, down 1.0%, at 754.15.The Cboe UK 100 ended down 0.4% at 766.89, the Cboe UK 250 closed down 1.1% at 16,780

The FTSE 100 went into the afternoon on the back foot in tepid trade with US data and Federal Reserve meeting minutes ahead.The FTSE 100 index was down 69.86 points, or 0.9%, at 7,651.66. London?s large-cap index turned 40 on Wednesday.The FTSE 250 was down 174.90 points, 0.9%, at 19,336.90, and the AIM All-Share was down 5.84 points, 0.8%, at 755.71.The Cboe UK 100 was down 0.8% at 764.47, the Cb